Gene and Protein Expression Profiles of Anti‐ and Pro‐apoptotic Actions of Dopamine, R‐Apomorphine, Green Tea Polyphenol (−)‐Epigallocatechine‐3‐gallate, and Melatonin
暂无分享,去创建一个
[1] S. Cory,et al. The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.
[2] Yona Levites,et al. Involvement of Protein Kinase C Activation and Cell Survival/ Cell Cycle Genes in Green Tea Polyphenol (−)-Epigallocatechin 3-Gallate Neuroprotective Action* , 2002, The Journal of Biological Chemistry.
[3] F. Herrera,et al. Protective effect of melatonin in a chronic experimental model of Parkinson’s disease , 2002, Brain Research.
[4] Wei Wei,et al. Melatonin blocks rat hippocampal neuronal apoptosis induced by amyloid beta‐peptide 25–35 , 2002, Journal of pineal research.
[5] M. Naoi,et al. The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells , 2002, Journal of Neural Transmission.
[6] C. Hess,et al. Melatonin protects SHSY5Y neuroblastoma cells from cobalt‐induced oxidative stress, neurotoxicity and increased β‐amyloid secretion , 2001, Journal of pineal research.
[7] S. Korsmeyer,et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. , 2001, Molecular cell.
[8] S. Mandel,et al. Green tea polyphenol (–)‐epigallocatechin‐3‐gallate prevents N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced dopaminergic neurodegeneration , 2001, Journal of neurochemistry.
[9] Y. Akao,et al. Transfection‐enforced Bcl‐2 overexpression and an anti‐Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde‐3‐phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N‐methyl(R)salsolinol , 2001, Journal of neurochemistry.
[10] P. Liebmann,et al. Prooxidant activity of melatonin promotes fas‐induced cell death in human leukemic Jurkat cells , 2001, FEBS letters.
[11] S. Mandel,et al. Gene expression analysis in N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R‐apomorphine , 2001, Journal of neurochemistry.
[12] A. Barzilai,et al. Is There a Rationale for Neuroprotection Against Dopamine Toxicity in Parkinson's Disease? , 2001, Cellular and Molecular Neurobiology.
[13] P. Bernardi,et al. A mitochondrial perspective on cell death. , 2001, Trends in biochemical sciences.
[14] R. Reiter,et al. Melatonin as a Pharmacological Agent against Neuronal Loss in Experimental Models of Huntington's Disease, Alzheimer's Disease and Parkinsonism , 1999, Annals of the New York Academy of Sciences.
[15] S. Mandel,et al. Apomorphine protects against MPTP‐induced neurotoxicity in mice , 1999, Movement disorders : official journal of the Movement Disorder Society.
[16] M. M. Esteban,et al. Melatonin prevents apoptosis induced by 6‐hydroxydopamine in neuronal cells: Implications for Parkinson's disease , 1998, Journal of pineal research.
[17] H. Baas,et al. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. , 1998, Clinical neuropharmacology.
[18] P Riederer,et al. Iron in the Parkinsonian substantia nigra. , 1997, Movement disorders : official journal of the Movement Disorder Society.
[19] T. Ratovitski,et al. DOPAMINE-INDUCED APOPTOSIS IN HUMAN NEURONAL CELLS: INHIBITION BY NUCLEIC ACIDS ANTISENSE TO THE DOPAMINE TRANSPORTER , 1996, Neuroscience.
[20] K. Jellinger,et al. Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease. , 1996, Biochimica et biophysica acta.
[21] A. Barzilai,et al. Dopamine-induced programmed cell death in mouse thymocytes. , 1995, Biochimica et biophysica acta.
[22] C. Waters,et al. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. , 1995, The Journal of clinical investigation.
[23] C. Waters,et al. Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis , 1994, Neuroscience.
[24] Barry Halliwell,et al. Reactive Oxygen Species and the Central Nervous System , 1992, Journal of neurochemistry.
[25] R. Todd. Neural development is regulated by classical neurotransmitters: Dopamine D2 receptor stimulation enhances neurite outgrowth , 1992, Biological Psychiatry.
[26] Peter Riederer,et al. Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.
[27] D. Jacobowitz,et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[28] H. Thoenen,et al. Model experiments on the molecular mechanism of action of 6-hydroxydopamine. , 1971, Molecular pharmacology.
[29] S. Mandel,et al. Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. , 2002, Biochemical pharmacology.
[30] K. Jellinger,et al. The pathology of Parkinson's disease. , 2001, Advances in neurology.
[31] S. Mandel,et al. Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression. , 2001, Advances in neurology.
[32] K. Jellinger. Cell death mechanisms in Parkinson's disease , 2000, Journal of Neural Transmission.
[33] S. Mandel,et al. Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine. , 2000, Journal of neural transmission. Supplementum.
[34] M. Youdim,et al. Apomorphine is a potent radical scavenger and protects cultured pheochromocytoma cells from 6-OHDA and H2O2-induced cell death. , 1998, Advances in pharmacology.
[35] M. Youdim,et al. Antioxidant and Cytoprotective Properties of Apomorphine , 1998 .
[36] P. Riederer,et al. Oxidative stress: free radical production in neural degeneration. , 1994, Pharmacology & therapeutics.
[37] P. Riederer,et al. Oxidative stress: a role in the pathogenesis of Parkinson's disease. , 1990, Journal of neural transmission. Supplementum.